Explore the vast range of titles available.

Hop (Humulus lupulus L.) is recognized as a valuable source of bioactive compounds; however, the phytochemical composition and biological potential of wild Romanian hops remain insufficiently characterized. In this study, the bioactive profile of wild hop cones was evaluated using an integrated phytochemical, biological, and in silico approach. The hydroethanolic extract was characterized by a total phenolic content of 25.61 mg GAE/g DW and a total flavonoid content of 3.20 mg RE/g DW, with α-acids predominating (8.77%) and β-acids detected only at trace levels (0.15%). Hydrodistillation yielded 0.613 ± 0.11% essential oil, which was rich in sesquiterpene hydrocarbons (64.61%), mainly α-humulene, β-caryophyllene oxide, selina-3,7-diene, and germacrene B. The hydroethanolic extract exhibited strong antioxidant activity (IC50 = 5.03 µg GAE/mL), whereas the essential oil showed a moderate but dose-dependent radical-scavenging capacity (IC50 = 0.44% v/v). In addition, the essential oil displayed pronounced antibacterial and antibiofilm activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, at 25 mg/mL, with the highest antibiofilm inhibition observed for Pseudomonas aeruginosa (96.44%). Molecular docking analysis suggested that the major volatile constituents may interact with Staphylococcus aureus Sortase A, providing a plausible mechanistic basis for the observed antibiofilm effects. Overall, these findings indicate that wild Romanian hop cones represent a promising source of antioxidant and antimicrobial bioactive compounds, supporting their potential applications in pharmaceutical, food, and cosmetic formulations, as well as in natural-product-based drug discovery.

Three poplar species widely distributed in southern Romania were investigated for their chemical composition and bioactivity. Male buds from black poplar (Populus nigra L.), white poplar (Populus alba L.), and Euroamerican hybrid poplar (Populus × euramericana (Dode) Guinier.) were analyzed using HPTLC, HPLC, GC-MS, and spectrophotometric assays. The analysis revealed predominantly polyphenolic compounds, including phenolic acids and flavonoids, secondary metabolites recognized for their antioxidant properties, particularly valuable in alleviating oxidative stress disorders. Heavy metal content was measured using atomic absorption spectroscopy, and antioxidant capacity was assessed through DPPH and FRAP assays alongside a cytotoxicity evaluation. Polyphenolic content ranged from 19.26 to 33.37 mg GAE/g DW and flavonoid content from 2.15 to 4.45 mg RE/g DW. All three species demonstrated notable antioxidant capacity and cytotoxic activity. Hydroethanolic extracts of P. nigra and P. euramericana showed higher antioxidant activity than aqueous extracts, with P. nigra achieving the lowest IC50 value overall, highlighting the influence of solvent choice on antioxidant efficacy. Furthermore, poplar hydroethanolic extracts exhibited concentration-dependent cytotoxicity against fibroblast-like human osteosarcoma MG63 cell lines, with IC50 values of 42.55 µg/mL for P. nigra, 40.87 µg/mL for P. × euramericana, and 132.49 µg/mL for P. alba, underscoring significant interspecies variability in cytotoxic potency. These findings suggest that male floral buds from Romanian poplar species may serve as valuable sources of bioactive compounds with therapeutic potential.

Background/Objectives: Rivaroxaban, an oral anticoagulant, shows poor aqueous solubility, posing significant challenges to its bioavailability and therapeutic efficiency. The present study investigates the improvement of rivaroxaban’s solubility through the formation of different inclusion complexes with three cyclodextrin derivatives, such as β-cyclodextrin (β-CD), methyl-β-cyclodextrin (Me-β-CD), and hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by lyophilization in order to stabilize the complexes and improve dissolution characteristics of rivaroxaban. Methods: The physicochemical properties of the individual compounds and the three lyophilized complexes were analysed using Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), X-ray diffraction (XRD), and thermogravimetric analysis (TGA). Results: FTIR spectra confirmed the formation of non-covalent interactions between rivaroxaban and the cyclodextrins, suggesting successful encapsulation into cyclodextrin cavity. SEM images revealed a significant morphological transformation from the crystalline structure of pure rivaroxaban and cyclodextrins morphologies to a more porous and amorphous matrix in all lyophilized complexes. XRD patterns indicated a noticeable reduction in drug crystallinity, supporting enhanced potential of the drug solubility. TGA analysis demonstrated improved thermal stability in the inclusion complexes compared to the individual drug and cyclodextrins. Pharmacotechnical evaluation revealed that the obtained formulations (by comparison with physical mixtures formulations) possessed favorable bulk and tapped density values, suitable compressibility index, and good flow properties, making all suitable for direct compression into solid dosage forms. Conclusions: The improved cyclodextrins formulation characteristics, combined with enhanced dissolution profiles of rivaroxaban comparable to commercial Xarelto® 10 mg, highlight the potential of both cyclodextrin inclusion and lyophilization technique as synergistic strategies for enhancing the solubility and drug release of rivaroxaban.

The present study investigates the co-crystallization process of rivaroxaban (RIV), a poorly water-soluble potent oral anticoagulant, with niacinamide (NIA), a highly soluble and pharmaceutically acceptable co-crystal former, in two different molar ratios (1:1 and 1:2). The aim was to enhance the physicochemical and biopharmaceutical properties of rivaroxaban such as dissolution rate and aqueous solubility, by forming stable co-crystals through a solvent evaporation technique. The resulting co-crystals (RIV-NIA, 1:1 co-crystallization compound, F1 and RIV-NIA, 1:2 co-crystallization compound, F3) were characterized using scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FTIR), powder X-ray diffraction (XRD) and thermal analysis, which confirmed the formation of a new rivaroxaban–niacinamide co-crystalline phase. In vitro dissolution studies confirmed a significant enhancement in the dissolution rate of the two obtained co-crystals. These findings suggest that stoichiometric variation plays an important role in co-crystal performance and in improving solubility compared with the pure drug. Also, the obtained results suggest that niacinamide is an effective coformer for improving the dissolution and physicochemical properties of rivaroxaban.